BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35261949)

  • 1. Impact of the KIT/PDGFRA genotype on prognosis in imatinib-naïve Japanese patients with gastrointestinal stromal tumor.
    Cho H; Nishida T; Takahashi T; Masuzawa T; Hirota S
    Ann Gastroenterol Surg; 2022 Mar; 6(2):241-248. PubMed ID: 35261949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
    JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutational characteristics of gastrointestinal stromal tumors: A single-center analysis of 302 patients.
    Liang L; Li X; Li D; Liu P; Nong L; Dong Y; Liu J; Huang S; Li T
    Oncol Lett; 2021 Feb; 21(2):174. PubMed ID: 33552291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
    Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
    Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
    Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
    Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.
    Joensuu H; Rutkowski P; Nishida T; Steigen SE; Brabec P; Plank L; Nilsson B; Braconi C; Bordoni A; Magnusson MK; Sufliarsky J; Federico M; Jonasson JG; Hostein I; Bringuier PP; Emile JF
    J Clin Oncol; 2015 Feb; 33(6):634-42. PubMed ID: 25605837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
    Ali Abuderman AW; M Aldakheel F
    Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
    Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
    Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
    Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
    Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
    Bombac A; Zakotnik B; Bucic M; Setrajcic Dragos V; Gazic B; Stegel V; Klancar G; Novakovic S
    Int J Oncol; 2020 Jun; 56(6):1468-1478. PubMed ID: 32236636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
    Qi C; Pan F; Li J; Li Y; Gao J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1280-1284. PubMed ID: 30506540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience.
    Wozniak A; Rutkowski P; Piskorz A; Ciwoniuk M; Osuch C; Bylina E; Sygut J; Chosia M; Rys J; Urbanczyk K; Kruszewski W; Sowa P; Siedlecki J; Debiec-Rychter M; Limon J;
    Ann Oncol; 2012 Feb; 23(2):353-60. PubMed ID: 21527588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
    Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
    [No Abstract]   [Full Text] [Related]  

  • 20. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
    Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
    J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.